VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-1.18%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$496M
AUM Growth
+$22M
(+4.6%)
Cap. Flow
+$35.1M
Cap. Flow
% of AUM
7.06%
Top 10 Holdings %
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26
Top Buys
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$6.67M |
| 2 |
ECC
Eagle Point Credit Co
ECC
|
$5.43M |
| 3 |
ANDX
Andeavor Logistics LP
ANDX
|
$2.66M |
| 4 |
BlackRock Floating Rate Income Strategies Fund
FRA
|
$2.25M |
| 5 |
MVC
MVC Capital, Inc.
MVC
|
$1.95M |
Sector Composition
| 1 | Financials | 24.1% |
| 2 | Real Estate | 16.28% |
| 3 | Energy | 14.42% |
| 4 | Healthcare | 8.59% |
| 5 | Materials | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Bain Capital Specialty
BCSF
$1.02B
| $956K | 0.19% |
+51,335
| New | +$956K |
|
|
SGEN
152
DELISTED
Seagen Inc. Common Stock
SGEN
| $864K | 0.17% |
10,120
-1,697
| -14% | -$145K |
|
153
Theravance Biopharma
TBPH
$713M
| $846K | 0.17% |
43,442
-7,309
| -14% | -$142K |
|
|
RDUS
154
DELISTED
Radius Health, Inc.
RDUS
| $811K | 0.16% |
31,498
-5,297
| -14% | -$136K |
|
155
Alnylam Pharmaceuticals
ALNY
$59.4B
| $795K | 0.16% |
9,888
-1,671
| -14% | -$134K |
|
156
Amgen
AMGN
$152B
| $762K | 0.15% |
3,939
-658
| -14% | -$127K |
|
|
MNTA
157
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $750K | 0.15% |
57,849
-9,721
| -14% | -$126K |
|
158
Neurocrine Biosciences
NBIX
$14.1B
| $743K | 0.15% |
8,250
-1,396
| -14% | -$126K |
|
159
Biogen
BIIB
$20.7B
| $738K | 0.15% |
3,170
-386
| -11% | -$89.9K |
|
|
PTLA
160
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $722K | 0.15% |
26,910
-4,526
| -14% | -$121K |
|
|
CELG
161
DELISTED
Celgene Corp
CELG
| $712K | 0.14% |
7,171
-1,217
| -15% | -$121K |
|
162
United Therapeutics
UTHR
$17.3B
| $706K | 0.14% |
8,856
-1,492
| -14% | -$119K |
|
163
Gilead Sciences
GILD
$141B
| $699K | 0.14% |
11,032
-1,762
| -14% | -$112K |
|
164
Omeros
OMER
$290M
| $699K | 0.14% |
42,784
-7,184
| -14% | -$117K |
|
165
Vertex Pharmaceuticals
VRTX
$102B
| $689K | 0.14% |
4,068
-688
| -14% | -$117K |
|
166
Halozyme
HALO
$8.56B
| $683K | 0.14% |
44,046
-7,415
| -14% | -$115K |
|
167
Ionis Pharmaceuticals
IONS
$9.5B
| $668K | 0.13% |
11,156
-1,881
| -14% | -$113K |
|
168
Incyte
INCY
$16.7B
| $661K | 0.13% |
8,911
-1,506
| -14% | -$112K |
|
169
Ligand Pharmaceuticals
LGND
$3.3B
| $643K | 0.13% |
10,347
-1,733
| -14% | -$108K |
|
170
Regeneron Pharmaceuticals
REGN
$60.4B
| $630K | 0.13% |
2,271
-381
| -14% | -$106K |
|
171
Vanda Pharmaceuticals
VNDA
$277M
| $630K | 0.13% |
47,470
-7,974
| -14% | -$106K |
|
172
Exelixis
EXEL
$10.1B
| $622K | 0.13% |
35,178
-5,913
| -14% | -$105K |
|
|
ALXN
173
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $594K | 0.12% |
6,063
-801
| -12% | -$78.5K |
|
174
Puma Biotechnology
PBYI
$261M
| $582K | 0.12% |
54,053
-9,089
| -14% | -$97.9K |
|
|
ICPT
175
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $578K | 0.12% |
8,711
-1,469
| -14% | -$97.5K |
|